On a per-share basis, the
The results beat
The biopharmaceutical company posted revenue of
Concert shares have climbed roughly 2% since the beginning of the year. The stock has declined 10% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a
Automated Insights, source